Liggins Institute seminars: "The relationship between adult height and cancer risk" and "Identification of biomarkers predicting endocrine therapy responsiveness in breast cancer" Event as iCalendar

06 November 2013

4 - 5pm

Venue: Seminar Room 505-003, Building 505, 85 Park Road, Grafton

The relationship between adult height and cancer risk

Increasing adult height is a widely accepted marker of health and nutritional status, and is inversely associated with the risk of mortality from certain diseases. However, tallness in adults is also associated with an increased risk of certain malignancies such as breast cancer. Evidence supporting the relationship between adult height and cancer risk will be presented.

Presented by Dr Jo Perry

Identification of biomarkers predicting endocrine therapy responsiveness in breast cancer

Endocrine therapies remain the most effective form of systemic therapy for estrogen receptor positive (ER+) patients. They include the use of SERMs (selective ER modulators) to inhibit estrogen’s action in breast tissue, or aromatase inhibitors to block the production of estrogen from androgens in the body. However, a significant proportion of ER+ breast tumours initially responsive to these therapies develop resistance and up to 40-50% of patients relapse. Therefore, there is an urgent need to develop a robust clinical biomarker to predict response to endocrine therapies. I will discuss our latest finding that SHON (Secreted Hominoid-specific ONcogene), an estrogen regulated gene, may be a novel predictive biomarker of patient response to endocrine therapy in ER+ breast cancer.

Presented by Dr Dongxu Liu